Phase II evaluation of AT-1727 in advanced human cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010879:Piperazines; C031186:bimolane; D011929:Razoxane